Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Symptomatic Transthyretin Amyloid Cardiomyopathy”

6 trials

Showing 6 of 6 results

Large-scale testing (Phase 3)Study completedNCT03860935
What this trial is testing

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

Who this might be right for
AmyloidosisAmyloid CardiomyopathyTransthyretin Amyloidosis+2 more
Eidos Therapeutics, a BridgeBio company 632
Large-scale testing (Phase 3)Active Not RecruitingNCT04988386
What this trial is testing

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Who this might be right for
Amyloid Cardiomyopathy, Transthyretin-Related
Eidos Therapeutics, a BridgeBio company 389
Large-scale testing (Phase 3)Study completedNCT04622046
What this trial is testing

ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

Who this might be right for
Symptomatic Transthyretin Amyloid Cardiomyopathy
Alexion Pharmaceuticals, Inc. 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT03536767
What this trial is testing

Open-Label Study of AG10 in Patients with Cardiomyopathy

Who this might be right for
Amyloid Cardiomyopathy
Eidos Therapeutics, a BridgeBio company 55
Not applicableUnknownNCT05754099
What this trial is testing

Identification of Clinically Significant Markers of ATTRv in Pre-symptomatic Mutation Carriers.

Who this might be right for
Amyloidosis
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 20
Testing effectiveness (Phase 2)Study completedNCT03458130
What this trial is testing

Study of AG10 in Amyloid Cardiomyopathy

Who this might be right for
Familial ATTR-CM (ATTRm-CM, or FAC)Wild-type ATTR-CM (ATTRwt-CM)
Eidos Therapeutics, a BridgeBio company 49

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation